Log In
BCIQ
Print this Print this
 

SC-003

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionAntibody-drug conjugate (ADC) comprised of a mAb linked to a potent chemotherapy
Molecular Target
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationOvarian cancer
Indication DetailsTreat ovarian cancer; Treat platinum-resistant and refractory ovarian cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$9,800.0M

$2,000.0M

$4,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2016

$9,800.0M

$2,000.0M

$4,000.0M

Get a free BioCentury trial today